Public assistance and survival equality in patients with <i>EGFR</i> mutation-positive lung cancer
Kiyoaki Uryu(Yao Tokushukai General Hospital), Hironobu Minami(Kobe University), Yoshiaki Fujimura(Fukuoka Tokushukai Hospital), Tomoya Fukui(Wakayama Medical University), Rai Shimoyama(Fukuoka Tokushukai Hospital), Yoshinori Imamura(Kobe University), Akihiko Iwase(Chiba-Nishi General Hospital), Yusuke Chihara(Fukuoka Tokushukai Hospital), Takafumi Okabe(Dana-Farber Cancer Institute), Makoto Hibino(Fujisawa City Hospital), Maki Hayashi(Mirai Hospital), Yukihiro Tamura(Azumi Hospital), Ryuta Fukai(Shonan Kamakura General Hospital), T. Mase, Masahiro Fukuoka(National Institute of Standards and Technology), Megu Ohtaki(Hiroshima University), Noriko Yamada(University of Washington), Asuka Tsuya(Izumi City General Hospital), Hiromasa Harada(Fukuoka Tokushukai Hospital), Shigeto Horiuchi(Fujisawa City Hospital), Keiko Otani(Hiroshima University)
Cited by 1
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer
|Oncology Reports|2015|852
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670